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Abstract
Introduction. Asymptomatic hyperuricemia is an established independent risk factor for cardiovascular (CV) disease. 
However, the awareness of this fact among physicians is still insufficient. Data are also lacking on the prevalence of 
asymptomatic hyperuricemia in a population of patients potentially requiring drug therapy.
The aim of the study was to assess the prevalence of asymptomatic hyperuricemia in the population of patients hospi-
talized in an internal medicine unit and the frequency of use of uricosuric drugs in this group of patients.
Material and methods. Single centre retrospective cohort study — evaluation of medical records of patients hospitalized 
in an internal medicine unit in the first half of 2018. The analysis included biochemical testing results, data on patients’ 
medical conditions and drug therapy used. Based on the collected data, a group of patients with a very high CV risk 
was identified in whom serum uric acid level ≥ 5 mg/dL is considered abnormal. Typical statistical methods were used 
including descriptive statistics, appropriate parametric and non-parametric tests to evaluate significance of differences 
in the values of selected parameters between the study groups, and generalized regression models. Statistically signi-
ficant differences were conventionally defined as p < 0.05.
Results. The analysis included data from 354 patients, of whom 194 (55%) met the criteria of a very high CV risk. 
These patients were older (75 vs. 62 years, p < 0.001) and had lower glomerular filtration rate values (85 vs. 118 mL/ 
/min/1.73 m2, p = 0.04) and higher mean serum uric acid level (6.6 vs. 5.5 mg/dL, p < 0.001) compared to the control 
group (non-very high CV risk patients). No significant differences in lipid levels were found between the two groups. Se-
rum uric acid level was measured in 55% of patients in the very high CV risk group. Abnormal renal function parameters 
were an independent predictor of serum uric acid level above 5 mg/dL in this group (R2 = 0.18, p < 0.001). Serum uric 
acid level was above 5 mg/dL in 70% of very high CV risk patients in whom it was measured. Allopurinol was used in 
only 25% of these patients, and the mean serum uric acid level in those receiving uricosuric treatment was 8.1 mg/dL. 
The most commonly used allopurinol dose was 100 mg/day. The mean serum uric acid level in patients not receiving 
uricosuric treatment was 6.2 mg/dL.
Conclusions. Serum uric acid level measurement is too rarely considered in the biochemical profile of patients at a very 
high CV risk. Serum uric acid level may be an indication for the use of uricosuric drugs in most patients at a very high CV 
risk. In the light of the current expert consensus, allopurinol is underused and underdosed in the very high CV risk group.
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Introduction
Clinically, hyperuricemia has been traditionally associated 
with rheumatological and oncological disease. However, 
gout develops in only 30% of subjects with hyperuricemia, 
and an asymptomatic increase in serum acid level is an 
established but still underrated independent risk factor 
for cardiovascular disease [1–2]. In the general popu-
lation, serum uric acid level in the range of 3–7 mg/dL 
(180–420 µmol/L) is considered normal, and for many 
years, the European League Against Rheumatism (EULAR) 
recommended to treat asymptomatic hyperuricemia only 
when serum uric acid level was > 12 mg/dL [3–6]. Current-
ly, however, there is an expert consensus that asymptomatic 
hyperuricemia is associated with an increased risk of dia-
betes type 2, hypertension, chronic kidney disease, and 
cardiovascular mortality. Asymptomatic hyperuricemia be-
comes clinically important already at serum uric acid levels 
below 7 mg/dL [7–13]. Target serum uric acid level should 
be < 5 mg/dL in patients with at least two of the following 
conditions: hypertension, diabetes, dyslipidaemia, chronic 
kidney disease, recent myocardial infarction or stroke 
[13]. However, data are still lacking on the prevalence of 
asymptomatic hyperuricemia as defined above in patients 
at high cardiovascular risk, and on its effect on therapeutic 
decision making in the context of uricosuric drug use.
The aim of the study was to evaluate retrospectively 
the frequency of serum uric acid level measurements in 
patients admitted to an internal medicine unit. We also 
evaluated the relation between measured serum uric acid 
levels and therapeutic decisions in the context of treating 
hyperuricemia depending on the patient cardiovascular 
risk.
Material and methods
We retrospectively evaluated admissions to the Internal 
Medicine Unit of the Międzylesie Specialist Hospital from 
January 1 to June 30, 2018. The analysis did not include 
hospitalizations that led to a patient’s death. Very high 
cardiovascular risk was defined as the presence of gene-
ralized atherosclerosis (based on the data from medical 
history and/or hospital discharge diagnoses) or concomi-
tant presence of at least two of the following conditions: 
hypertension, diabetes, chronic kidney disease [glomerular 
filtration rate (GFR) < 60 mL/min/1.73 m2], ischaemic heart 
disease (previous myocardial infarction, coronary artery 
bypass grafting or percutaneous coronary intervention, 
stable ischemic heart disease), or previous stroke. The 
control group included patients who did not meet the above 
criteria of a very high cardiovascular risk. The two groups 
were compared in regard to renal function, lipid profile, 
serum uric acid level, age, comorbidities, and treatment 
with allopurinol. In case of repeated admissions, the one 
with serum uric acid level measurement was included in the 
analysis. If serum uric acid level was not measured during 
any of the repeated admissions, the one that provided the 
most of the analysed data was included in the analysis. 
Statistical analysis was performed using the STATISTICA 12 
PL software. Significance of the differences in quantitative 
variables was assessed using the Student t test or the 
Mann-Whitney U test, depending on variable distribution. 
Significance of the differences in categorical variables was 
assessed using the chi-square test. Generalized linear 
regression models were used to evaluate variables that 
had an effect on the decision to measure serum uric acid 
level and to treat hyperuricemia in patients at a very high 
cardiovascular risk. For all tests, statistical significance 
was set at p < 0.05.
Results
Among 428 admissions from January 1 to June 30, 2018, 
50 led to the patient’s death and were not included in the 
analysis. Of the remaining 378 admissions, 18 patients 
were hospitalized more than once (range 2–5). Ultimately, 
data from 354 admissions were included in the analysis, 
with 194 (55%) patients assigned to the very high cardio-
vascular risk group (Group A), and the remaining 160 (45%) 
patients not fulfilling the very high cardiovascular risk cri-
teria as defined in the methods (Group B). The patients in 
Group A were older (75 vs. 62 years, p < 0.001), had higher 
mean serum uric acid level (6.6 vs. 5.5 mg/dL, p < 0.001; 
Figure 1), and lower GFR (85 vs. 118 mL/min/1.73 m2, 
p = 0.04). We did not find significant differences in lipid 
levels between the two groups (Table 1). Serum uric acid 
level was measured in 55% patients in Group A and 45% 
Figure 1. Box plot for serum uric acid level in the study population: 
very high cardiovascular risk group vs. control group
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patients in Group B. In both groups, serum uric acid level 
showed a moderate but significant negative correlation with 
GFR (r = –0.4). In the very high cardiovascular risk group, 
a positive correlation was also seen with age (r = 0.25), 
urea level (r = 0.45) but not creatinine, and triglyceride 
level (r = 0.25). However, regression analysis showed that 
abnormal renal function was the only independent predictor 
of serum uric acid level > 5 mg/dl (R2 = 0.18, p < 0.001).
In 70% of patients in Group A in whom serum uric acid 
level was measured, it was higher than 5 mg/dL. Allopurinol 
was given in only 25% of these patients (Figure 2). The 
mean serum uric acid level in these patients was 8.1 mg/dL 
compared to 6.2 mg/dL in those in whom allopurinol was 
not used.
Among concomitant conditions, the likelihood of serum 
uric acid level measurement was increased by the presence 
of diabetes, and concomitant chronic kidney disease affec-
ted whether allopurinol was given (Figures 3 and 4). The 
most commonly used allopurinol dose was 100 mg/day. No 
correlation was found between allopurinol dose and serum 
uric acid level. No difference in the mean drug dose was 
found between the evaluated subgroups.
Discussion
Serum uric acid level is currently considered not only an 
independent risk factor for cardiovascular disease but also 
an independent risk factor for mortality [13]. Ndrepepa et 
Table 1. Study population characteristics (age and biochemical testing results) in the very high cardiovascular (CV) risk group and the 
control group
Variable 
(mean ± SD)
Very high CV risk group 
(N = 194)
Control group 
(N = 160)
p
Age [years] 75.51 (± 11.9) 62.06 (± 18.6) < 0.001
GFR [mL/min/1.73 m2] 85.39 (± 43.8) 118.00 (± 51.2) < 0.001
Creatinine [mg/dL] 1.24 (± 0.3) 0.77 (± 0.3) < 0.001
Urea [mg/dL] 48.76 (± 28.8) 32.53 (± 19.8) < 0.001
Uric acid [mg/dL] 6.57 (± 3.1) 5.48 (± 2.14) 0.01
Total cholesterol [mg/dL] 147.17 (± 47.6) 154.08 (± 52.9) 0.28
HDL cholesterol [mg/dL] 39.87 (± 13.5) 42.32 (± 15.9) 0.19
LDL cholesterol [mg/dL] 82.11 (± 35.7) 84.86 (± 33.2) 0.54
TG [mg/dL] 127.59 (± 73.3) 136.32 (± 155.1) 0.56
SD — standard deviation; GFR — glomerular filtration rate; HDL — high-density lipoprotein; LDL — low-density lipoprotein; TG — triglycerides
Figure 2. Patient flowchart showing serum uric acid measurements, prevalence of hyperuricemia, and allopurinol use in the study population
428 hospitalizations
50 deaths
18 patients admitted more than one
354 hospitalizations included in the analysis
160 patients not fulfilling very high 
cardiovascular risk criteria
194 patients with very high 
cardiovascular risk
73 (45%) patients with serum 
uric acid level measured
108 (55%) patients with serum 
uric acid level measured
Serum uric acid > 5 mg/dL 
in 41 (56%) patients
Serum uric acid > 5 mg/dL 
in 76 (70%) patients
9 (8%) patients treated 
with allopurinol
23 (21%) patients treated 
with allopurinol
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al. [14] studied more than 5000 patients after an acute 
coronary syndrome and showed that after adjustment 
for conventional risk factors, each increase in serum uric 
acid level by 1 mg/dL was associated with an increase 
in the mortality risk by 12%. Korean authors reviewed 
medical data of more than 370,000 patients and found 
a U-shaped relationship between serum uric acid level 
and the risk of death. Serum uric acid level < 3.5 mg/dL 
in men and < 2.5 mg/dL in women was associated with 
a 58% and 80% higher mortality risk, respectively (hazard 
ratio [HR] 1.58, 95% confidence interval [CI] 1.18–2.1, 
and HR 1.8, 95% CI 1.1–2.93). For hyperuricemia, the 
cut-off values were > 9.5 mg/dL in men and > 8.5 mg/dL 
in women, associated with HR 2.39 (95% CI 1.57–3.66) 
and 3.77 (95% CI 1.17–12.17) for mortality risk in men 
and women, respectively [15]. In the PreCis study, each 
increase in serum uric acid level by 1 mg/dL was associa-
ted with an increase in mortality risk by 39% [16]. In the 
PAMELA study which evaluated cardiovascular disease risk 
factors in a random sample of the general population, the 
highest sensitivity and specificity was found for the cut-off 
serum uric acid level of 5.4 mg/dL for the cardiovascular 
mortality and 4.9 mg/dL for the overall mortality [17]. It 
can be thus concluded that the measurement of serum 
uric acid level should be included in the routine bioche-
mical testing panel in hospitalized patients, particularly 
those at a very high cardiovascular risk. During our study 
period, however, this measurement was performed in our 
unit in only about half of patients at a very high cardiova-
scular risk. We have also shown that only the presence 
of diabetes independently increased the likelihood of the 
performance of this measurement. Paradoxically, this is 
justified by clinical studies but not guidelines. Liu et al. 
noted nephroprotective effects of allopurinol in patients 
with diabetes, along with a beneficial effect on insulin 
sensitivity and a reduction in high-sensitivity C-reactive 
protein (hsCRP) level and the intima-media thickness in 
the carotid arteries [18, 19]. However, current guidelines 
on the diagnosis and management of diabetes do not cover 
the issue of hyperuricemia at all [20]. Only the guidelines 
on the diagnosis and management of hypertension and 
rather obsolete 2013 guidelines on the management of 
stable coronary artery disease (new guidelines are to be 
published in 2019) mention the need to measure serum 
uric acid level and note the benefits of uricosuric drugs 
[21, 22]. In the guidelines on stable coronary artery 
disease, it has been highlighted that allopurinol has an-
tianginal properties in subjects without gout, may reduce 
oxidative stress, and when used at 600 mg per day, it may 
prolong exercise time not only to chest pain, but also to ST 
segment depression [22].
In the recent years, a number of expert consensuses 
have been published that indicate the need for more freq-
uent serum uric acid measurement and earlier initiation of 
uricosuric drugs [11, 13]. According to these documents, 
in patients with at least two metabolic and/or cardiovascu-
lar conditions, abnormal serum uric acid level should be 
defined as > 5 mg/dL in both genders [11, 13]. However, 
the prevalence of so defined asymptomatic hyperuricemia 
in the population of patients at a very high cardiovascular 
risk is not known. In our study, we have attempted to pro-
vide some early estimates the scope of this problem. For 
the purpose of our analyses, we defined the upper limit of 
normal values in patients at a very high cardiovascular risk 
as 5 mg/dl, consistent with the consensus by Borghi et al. 
[13]. Although a limitation of our study is its retrospective, 
single-centre nature, our findings indicate the need for 
more widespread educational efforts to promulgate the 
Figure 3. Main effects ANOVA. The effect of concomitant diabetes 
on the performance of serum uric acid level measurement. Verti-
cal red lines indicate the 95% confidence interval. Current effect: 
F(1.352) = 9.1431, p = 0.003
0.80
0 1
U
ri
c
 a
c
id
 l
e
v
e
l 
m
e
a
s
u
re
m
e
n
t
Diabetes mellitus
0.75
0.35
0.70
0.55
0.60
0.65
0.50
0.45
0.40
Figure 4. Main effects ANOVA. The effect of concomitant chro-
nic kidney disease on allopurinol use. Vertical red lines indicate 
the 95% confidence interval. Current effect: (1.349) = 17.197, 
p < 0.001
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studies in diabetic patients and the findings of Golmoham-
madi et al. suggest, however, that allopurinol use should 
be considered in particular in these patients [18, 19, 22, 
24]. At the same time Borghi et al. [25], in a study on the 
effects of allopurinol or probenecide in obese normotensive 
patients with serum uric acid level above 5 mg/dL, have 
questioned whether drug treatment of hyperuricemia has 
a protective effect on the endothelium.
Taking into account a large interest in the role of 
asymptomatic hyperuricemia as a contributor to the total 
cardiovascular risk in cardiac patients, the lack of data 
on the prevalence of asymptomatic hyperuricemia in this 
patient population in Poland, and ongoing uncertainties 
regarding chronic use of uricosuric drugs, a multicentre 
study seems warranted.
Conclusions
1. Serum uric acid level measurement is too rarely consi-
dered in the biochemical profile of patients at a very high 
cardiovascular risk. 2. Serum uric acid level may be an 
indication for the use of uricosuric drugs in most patients 
at a very high cardiovascular risk. 3. In the light of the 
current expert consensus, allopurinol is underused and 
underdosed in the very high cardiovascular risk group.
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knowledge on the importance of asymptomatic hyperu-
ricemia and the measurement of serum uric acid level in 
the population of patients at cardiac and metabolic risk. Of 
note, we observed a tendency to use a single, lowest allopu-
rinol dose. This is probably a result of long-held belief that 
uricosuric drug use is indicated only with much increased 
serum uric acid level and as chronic therapy in patients with 
a history of gout. It should also be noted that there is no 
consensus regarding the use of allopurinol doses exceeding 
100–300 mg per day. In the expert statement of the Polish 
Cardiac Society Cardiovascular Pharmacotherapy Commit-
tee, the use of very high doses (600–900 mg per day) has 
been considered reasonable [11]. In contrast, Borghi et al. 
[13] stated in their consensus that the efficacy and safety of 
chronic use of allopurinol doses exceeding 300 mg per day 
requires further studies. In a study in over 7,000 patients, 
Wei et al. [23] showed that the cardiovascular event rate 
showed an inverse correlation with allopurinol dose, as it 
was 74.0 (95% CI 61.9–86.1) per 1,000 person-years in the 
100 mg group compared to 69.7 (95% CI 49.6–99.8) per 
1000 person-years in the 200 mg group and 47.6 (95% CI 
38.4–56.9) per 1000 person-years in the ≥ 300 mg group. 
Use of allopurinol doses ≥ 300 mg/day vs. < 299 mg/day 
was associated with a lower risk of all-cause mortality 
(adjusted HR 0.65, 95% CI 0.42–0.99) [23]. Golmoham-
madi et al. indicated a potential nephroprotective effect of 
allopurinol [24]. In our study, abnormal renal function para-
meters were independently associated with the presence of 
hyperuricemia in the very high cardiovascular risk group. In 
the 2013 guidelines on the management of stable coronary 
artery disease, caution was advised when using uricosuric 
drugs in patients with reduced GFR. The above mentioned 
Streszczenie
Wstęp. Bezobjawowa hiperurykemia jest potwierdzonym i uznanym przez ekspertów niezależnym czynnikiem ryzyka 
sercowo-naczyniowego (CV). Świadomość tego faktu wśród lekarzy wciąż jednak pozostaje niewystarczająca. Brakuje 
również danych dotyczących rozpowszechnienia bezobjawowej hiperurykemii w populacji pacjentów potencjalnie wyma-
gających farmakoterapii.
Celem badania była ocena częstości występowania bezobjawowej hiperurykemii w populacji pacjentów hospitalizowa-
nych na oddziale internistycznym oraz częstości stosowania leków urykozurycznych w tej grupie chorych.
Materiał i metody. Jednoośrodkowe badanie kohortowe — retrospektywna ocena dokumentacji pacjentów hospitalizo-
wanych na oddziale internistycznym w pierwszym półroczu 2018 roku. W analizie uwzględniono wyniki badań bioche-
micznych, dane dotyczące chorobowości pacjentów oraz stosowanej farmakoterapii. Na podstawie zebranych danych 
wyodrębniono grupę pacjentów obciążonych bardzo wysokim ryzykiem CV, w odniesieniu do których za nieprawidłowe 
uznaje się stężenie kwasu moczowego większe lub równe 5 mg/dl. Zastosowano typowe metody statystyczne: staty-
styki opisowe, odpowiednie testy parametryczne i nieparametryczne w celu oceny istotności różnic wartości wybranych 
parametrów między badanymi grupami chorych oraz ogólne modele regresji. Przyjęto standardową wartość p poniżej 
0,05 dla różnic istotnych statystycznie.
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Wyniki. W analizie uwzględniono dane 354 pacjentów, spośród których 194 (55%) spełniło kryterium przynależności 
do grupy bardzo wysokiego ryzyka CV. Pozostali chorzy stanowili grupę kontrolną. Chorzy z grupy bardzo wysokiego 
ryzyka CV byli starsi (75 v. 62 lata; p < 0,001), wyróżniali się niższą wartością współczynnika filtracji kłębuszkowej 
(85 v. 118 ml/min/1,73 m2; p = 0,04) oraz wyższym średnim stężeniem kwasu moczowego (6,6 v. 5,5 mg/dl; p < 0,001). 
Nie wykazano natomiast istotnych różnic w stężeniach poszczególnych frakcji lipidogramu. Stężenie kwasu moczowego 
oznaczono u 55% pacjentów z grupy bardzo wysokiego ryzyka CV. Niezależnym predyktorem stężenia kwasu moczowego 
powyżej 5 mg/dl w tej grupie były nieprawidłowe parametry nerkowe (R2 = 0,18; p < 0,001). W przypadku 70% pacjentów 
z grupy bardzo wysokiego ryzyka CV, u których oznaczono stężenie kwasu moczowego, przekraczało ono 5 mg/dl. Allo-
purinol zastosowano jedynie u 25% tych chorych, przy czym średnie stężenie kwasu moczowego u pacjentów, u których 
włączono leczenie urykozuryczne, wynosiło 8,1 mg/dl. Najczęściej stosowaną dawką allopurinolu było 100 mg/dobę. 
Średnie stężenie kwasu moczowego u pacjentów, u których leczenia nie wdrożono, wynosiło 6,2 mg/dl.
Wnioski. Oznaczenie stężenia kwasu moczowego jest zbyt rzadko uwzględniane w profilu badań biochemicznych pacjen-
tów obciążonych bardzo wysokim ryzykiem CV. U większości pacjentów z grupy wysokiego ryzyka mogą istnieć wskazania 
do stosowania leków urykozurycznych. W świetle aktualnych konsensusów ekspertów allopurinol w grupie pacjentów 
obciążonych bardzo wysokim ryzykiem CV stosuje się zbyt rzadko i w zbyt małej dawce.
Słowa kluczowe: allopurinol, kwas moczowy
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